// App-Quantinova.ai

80 : Long-term treatment with sarilumab plus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): pooled safety and efficacy with over 4 years’ treatment

Researchers

Presenter

  • Hubert van Hoogstraten

Principal Investigators

  • Gregory St John

  • Karthinathan Thangavelu

  • Juan Jose Gomez-Reino

  • Jose Antonio Maldonado-Cocco

  • Juan Carlos Salazar

  • Thomas Huizinga

  • Elaine Wilson

  • Gerd R Burmester

Medical Centers

  • Medical Affairs, Sanofi, Bridgewater, NJ, USA

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Biostatistics, Sanofi Genzyme, Bridgewater, NJ

  • Rheumatology, IDIS, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, SPAIN

  • School of Medicine, Buenos Aires University, Buenos Aires, ARGENTINA

  • Rheumatology, Riesgo de Fractura S.A - CAYRE, Bogotá, COLOMBIA

  • Rheumatology, Leiden University Medical Centre, Leiden, NETHERLANDS

  • Rheumatology, Sanofi Genzyme, Oxford, UNITED KINGDOM

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

Locations

  • United States

  • Spain

  • Argentina

  • Colombia

  • Netherlands

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Sarilumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • NA

Study Id's

  • NCT01146652

  • NCT01061736

  • NCT01709578

  • NCT01768572

  • NCT01217814

  • NCT02121210

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved